Skip to main content
SpringerLink
Log in

Atypische Antidepressiva

  • Chapter
Book cover Neuro-Psychopharmaka

  • 47 Accesses

Zusammenfassung

Dem Terminus „atypisch“ kommt im Falle der Antidepressiva eine ähnliche uneinheitliche Konnotation zu wie bei den sogenannten atypischen Neuroleptika. So wird die heterogene Gruppe der chemisch neu-/andersartigen Antidepressiva häufig als „atypische Antidepressiva“ oder Antidepressiva der zweiten Generation den „klassischen“ tri- bzw. tetrazyklischen Antidepressiva gegenübergestellt. (Letztere werden im vorliegenden Band im Hauptkapitel 3. Nicht-trizyklische Antidepressiva abgehandelt.)

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 54.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Charney Ds, Heninger Md (1985) Noradrenergic function and the mechanism of action of anti-anxiety treatment. The effect of long-term alprazolam treatment. Arch Gen Psychiatry 42: 458–467

    Google Scholar 

  2. Eikmeier G, Berger M, Lodemann E et al. (1991) Trimipramine — an atypical neuroleptic? Int Clin Psychopharmacol 6: 147–153

    PubMed  CAS  Google Scholar 

  3. Gastpar M (1989) Clinical originality and new biology of trimipramine. Drugs 38 [Suppl 11: 43–48

    Google Scholar 

  4. Gross G, Xie X, Gastpar M (1991) Trimipramine: pharmacological reevaluation and comparison with clozapine. Neuropharmacology 30: 1159–1166

    PubMed  CAS  Google Scholar 

  5. Kramer M (1982) Dose-response effects of alprazolam on sleep architecture in normal subjects. Curr Ther Res 32: 960–968

    Google Scholar 

  6. Müller We (1991) Wirkungsmechanismus niedrigdosierter Neuroleptika bei Angst und Depression. In: Poldinger W (Hrsg) Niedrigdosierte Neuroleptika. Braun, Karlsruhe, S 24–36

    Google Scholar 

  7. Niemegeers CJE (1988) Pharmakologie und Biochemie niedrig dosierter Neuroleptika. In: Hippt0s H, Laakmann G (Hrsg) Therapie mit Neuroleptika — Niedrigdosierung. Perimed, Erlangen,S 10–18

    Google Scholar 

  8. Robertson Mm, Trimble Mr (1982) Major tranquilizers used as antidepressants. A review. J Affect Disord 4: 173–193

    Google Scholar 

  9. Schatzberg Af, Cole Jo (1978) Benzodiazepines in depressive disorders. Arch Gen Psychiatry 35: 1359–1365

    PubMed  CAS  Google Scholar 

  10. Sethy Vh, Hodges Dh (1985) Antidepressant activity of alprazolam in a reserpine-induced model of depression. Drug Dev Res 5: 179–184

    CAS  Google Scholar 

  11. Ungerstedt U, Herrera-Marschitz M, Sharp T, Stähle L, Tossmann U, Zetterström T (1985) Characterisation pharmacologique du dogma- til. Effets pre-et post-synaptiques sur les recepteurs dopaminergiques. Sem Hop Paris 61: 1283–1287

    Google Scholar 

  12. Von Voigtländer Pf, Straw Rn (1985) Alprazolam: review of pharmacological, pharmacokinetic, and clinical data. Drug Dev Res 6: 1–12

    Google Scholar 

  13. Wiegand M, Berger M, Zulley J, Von Zerssen D (1986) The effect of trimipramine on sleep in patients with major depressive disorder. Pharmacopsychiatry 19: 198–199

    CAS  Google Scholar 

  14. Abernethy Dr, Greenblatt Dj, Divoll M, Shader Ri (1983) Pharmacokinetics of alprazolam. J Clin Psychiatry 44 (Sec 2): 45–47

    PubMed  CAS  Google Scholar 

  15. Abernethy Dr, Greenblatt DJ, Shader RI (1984) Trimipramine kinetics and absolute bio-availability: use of gas-liquid chromatography with nitrogen-phosphorus detection. Clin Pharmacol Ther 35: 348–353

    PubMed  CAS  Google Scholar 

  16. Alfredsson G, Härnryd C, Wiesel FA (1984) Effects of sulpiride and chlorpromazine on depressive symptoms in schizophrenic patients — relationship to drug concentrations. Psychopharmacology 84: 237–241

    PubMed  CAS  Google Scholar 

  17. Dawson Gw, Jue Sg, Brogden Rn (1984) Alprazolam. A review of its pharmacodynamic properties and efficacy in the treatment of anxiety and depression. Drugs 27: 132–147

    Google Scholar 

  18. Degen J, Wölke E, Seiberling M, Pintar P, Höxter G, Steinhauer Hb, Fischer W (1993) Vergleichende Untersuchung zur Pharmakokinetik von Amitriptylinoxid und Trimipramin nach Einmalgabe bei gesunden männlichen Probanden und Patienten mit Niereninsuffizienz. Med Klin 88: 129–133

    CAS  Google Scholar 

  19. Douyon R, Angrist B, Peselow E, Cooper T, Rotrosen J (1989) Neuroleptic augmentation with alprazolam: clinical effects and pharmacokinetic correlates. Am J Psychiatry 146: 231–234

    PubMed  CAS  Google Scholar 

  20. Grasei.A Th Jr, Antal Ej, Ereshefsky L, Wells Bg, Evans Rl, Smith Rb (1987) An evaluation of population pharmacokinetics in therapeutic trials, part II. Detection of a drug-drug interaction. Clin Pharmacol Ther 42: 433–441

    Google Scholar 

  21. Jorgensen A (1986) Metabolism and pharmacokinetics of anti-psychotic drugs. Prog Drug Metab 9: 111–174

    Google Scholar 

  22. Kroboth PD, Mcauley JW, Smith RB (1990) Alprazolam in the elderly: pharmacokinetics and pharmacodynamics during multiple dosing. Psychopharmacology 100: 477–484

    PubMed  CAS  Google Scholar 

  23. Matheson I, Skjaeraasen J (1988) Milk concentrations of flupenthixol, nortriptyline and zuclopenthixol and between breast differences in two patients. Eur J Clin Pharmacol 35: 217–220

    PubMed  CAS  Google Scholar 

  24. Maurer H (1989) Metabolism of trimipramine in man. Arzneimittelforschung/Drug Res 39: 101–103

    CAS  Google Scholar 

  25. Simpson Gm, Pi Eh, Gross L, Baron D, November M (1988) Plasma levels and therapeutic response with trimipramine treatment of endogenous depression. J Clin Psychiatry 49: 113–116

    PubMed  CAS  Google Scholar 

  26. Smith Rb, Kroboth Pd, Vanderlugt Jt, Phillips Jp, Juhl Rp (1984) Pharmacokinetics and pharmacodynamics of alprazolam after oral and IV administration. Psychopharmacology 84: 452–456

    PubMed  CAS  Google Scholar 

  27. Trimble Mr, Robertson Mm (1983) Flupenthixol in depression. A study of serum levels and prolactin response. J Affect Dis 5: 81–89

    Google Scholar 

  28. Alvarez Fj, Velasco A, Palomares Jl (1988) Block- ade of muscarinic, histamine H1 and histamine H2 receptors by antidepressants. Pharmacology 37 (4): 225–231

    PubMed  CAS  Google Scholar 

  29. Bischoff S, Delini-Stula A, Maître L (1985) Blockade der Dopamin-Rezeptoren im Hippokampus als Indikator antipsychotische Wirksamkeit: Korrelationen zwischen neuro-chemischen und psychopharmakologischen Wirkungen von Neuroleptika. In: Pflug B, Foerster K, Straube E (Hrsg) Perspektiven der Schizophrenie-Forschung. Fischer, Stuttgart New York, S 87–103

    Google Scholar 

  30. Bond A, Silveira Jc, Lader M (1991) Effects of single doses of alprazolam and alcohol alone and in combination on psychological performance. Hum Psychopharmacol 6: 219–228

    CAS  Google Scholar 

  31. Burki Hr (1983) Neurobiochemische Wirkungen der Neuroleptika. In: Langer G, Heimann H (Hrsg) Psychopharmaka. Grundlagen und Therapie. Springer, Wien New York, 5 213–226

    Google Scholar 

  32. Carlsson A, Lindqvist M (1978) Effects of antidepressant agents on the synthesis of brain monoamines. J Neural Transm 43: 73–91

    PubMed  CAS  Google Scholar 

  33. Charney Ds, Breier A, Jatlow Pi, Heninger Gr (1986) Behavioral, biochemical, and blood pressure responses to alprazolam in healthy subjects: interactions with yohimbine. Psychopharmacology 88 (2): 133–140

    PubMed  CAS  Google Scholar 

  34. Contreras Pc, Bremer Me, Rao Ts (1990) Life Sci 47 (22): 133–137

    Google Scholar 

  35. Delini-Stula A (1983) Pharmakologie der Anti-depressiva. In: Langer G, Heimann H (Hrsg) Psychopharmaka. Grundlagen und Therapie. Springer, Wien New York, S 81–95

    Google Scholar 

  36. Di Micco JA (1987) Evidence for control of cardiac vagal tone by benzodiazepine receptors. Neuropharmacology 26 (6): 553–559

    Google Scholar 

  37. El-Fakahany E, Richelson E (1983) Antagonism by antidepressants of muscarinic acetylcholine receptor of human brain. Br J Pharmacol 78: 97–102

    PubMed  CAS  Google Scholar 

  38. Eriksson E, Carlsson M, Nilsson C, Sonderpalm B (1986) Does alprazolam, in contrast to diazepam, activate alpha 2-adrenoreceptors involved in the regulation of rat growth hormone secretion? Life Sci 38 (16): 1491–1498

    PubMed  CAS  Google Scholar 

  39. Gogolak G (1980) Neurophysiological properties (in animals) of antidepressants. Psycho-tropic Agents 55 (19): 415–435

    CAS  Google Scholar 

  40. Greenblatt Dj, Halmatz Js, Dorsey C, Shader Ri (1988) Comparative single-dose kinetics and dynamics of lorazepam, alprazolam, prazepam, and placebo. Clin Pharmacol Ther 44 (3): 326–334

    PubMed  CAS  Google Scholar 

  41. Gross G, Xie Xin, Gastpar M (1991) Trimipramine: pharmacological reevaluation and comparison with clozapine. Neuropharmacology 30 (11): 1159–1166

    PubMed  CAS  Google Scholar 

  42. Haefely We (1990) The GABA-A-benzodiazepine receptor: biology and pharmacology. In: burrows gd, roth m, noyes r jr (eds) The neurobiology of anxiety. Elsevier, Amsterdam, pp 165–188

    Google Scholar 

  43. Härnryd C, Bierkenstedt L, Gullberg B et al. (1984) Time course for effects of sulpiride and chlorpromazine on monoamine metabolite and prolactin levels in cerebrospinal fluid from schizophrenic patients. Acta Psychiatr Scand [Suppll 311: 75–92

    Google Scholar 

  44. Hyttel J (1982) Preferential labelling of adenylate cyclase coupled dopamine receptors with thioxantene neuroleptics. In: Kohsaka M, Shomori T, Tsukada Y, Woodruff Gn (eds) Advances in dopamine research. Pergamon, Oxford, pp 147–152

    Google Scholar 

  45. Hyttel J, Christensen Av (1983) Biochemical and pharmacological differentiation of neuroleptic effects on dopamine D1 and D2-receptors. J Neural Transm 18: 157–164

    CAS  Google Scholar 

  46. Hyttel J, Larsen Jj, Christensen Av, Arnt J (1985) Receptor binding profiles of neuroleptics. In: Casey De, Chase Tn, Christensen Av, Gerlachj (eds) Dyskinesia — research and treatment. Psychopharmacology 2: 9–18

    Google Scholar 

  47. Janke W (1964) Experimentelle Untersuchungen zur Abhängigkeit der Wirkung psychotoper Substanzen von Persönlichkeitsmerkmalen. Akademische Verlagsgesellschaft, Frankfurt

    Google Scholar 

  48. Köhler C, Ogren So, Hagglund L, Angely T (1979) Regional displacement by sulpiride of 3H-spiperone binding in vivo, biochemical and behavioural evidence of a preferential action on limbic and nigral dopamine receptors. Neurosci Lett 13: 51–56

    PubMed  Google Scholar 

  49. Kostowski W, Valzelli L, Baiguem G (1986) Effect of chronic administration of alprazolam and adinazolam on clonidine-or apomorphine-induced aggression in laboratory rodents. Neuropharmacology 25 (7): 757–761

    PubMed  CAS  Google Scholar 

  50. Kroboth Pd, Smith Rb, Erb Rj (1988) Tolerance to alprazolam after intravenous bolus and continuous infusion: psychomotor and EEG effects. Clin Pharmacol Ther 43: 270–277

    PubMed  CAS  Google Scholar 

  51. Lopez F, Miller Lg, Greenblatt Dj, Paul Sm, Shader Ri (1988) Low-dose alprazolam augments motor activity in mice. Pharmacol Biochem Behav 30 (2): 511–513

    PubMed  CAS  Google Scholar 

  52. Maj J, Przegalinski E, Mogilnicka E (1984) Hypo-theses concerning the mechanism of action of antidepressant drugs. Rev Physiol Biochem Pharmacol 100: 1–66

    PubMed  CAS  Google Scholar 

  53. Miller Lg, Grennblatt Dj, Barnhilljg, Deutsch Si, Shader Ri, Paul Sm (1987) Benzodiazepine receptor binding of triazolobenzodiazepines in vivo: increased receptor number with low-dose alprazolam. J Neurochem 49 (5): 1595–1601

    PubMed  CAS  Google Scholar 

  54. Moller-Nielsen I (1980) Tricyclic antidepressants: general pharmacology. Psychotropic Agents 55 (18): 399–414

    Google Scholar 

  55. Muller We (1991) Wirkungsmechanismus niedrigdosierter Neuroleptika bei Angst and Depression. In: Pöldinger W (Hrsg) Niedrig-dosierte Neuroleptika bei ängstlich-depressiven Zustandsbildern and psychomotorischen Erkrankungen. G Braun, Karlsruhe, S 24–38

    Google Scholar 

  56. O’connor Wt, Earley B, Leonard Be (1985) Antidepressant properties of the triazolobenzodiazepines alprazolam and adinazolam: studies on the olfactory bulbectomized rat model of depression. Br J Clin Pharmacol 19 (1): 49S - 56S

    PubMed  Google Scholar 

  57. Pöldinger W (1991) (Hrsg) Niedrigdosierte Neuroleptika bei ängstlich-depressiven Zustandsbildern and psychotischen Erkrankungen. G Braun, Karlsruhe

    Google Scholar 

  58. Randrup A, Braestrup C (1977) Uptake inhibition of biogenic amines by newer antidepressant drugs: relevance to the dopamine hypothesis of depression. Psychopharmacology 53: 309–314

    PubMed  CAS  Google Scholar 

  59. Richelson E (1991) Biological basis of depression and therapeutic relevance. J Clin Psychiatry 52: 4–10

    PubMed  Google Scholar 

  60. Richelson E, Nelson A (1984) Antagonism by antidepressants of neurotransmitter receptors of normal human brain in vitro. J Pharmacol Exp Ther 230: 94–102

    PubMed  CAS  Google Scholar 

  61. Richelson E, Pfenning M (1984) Blockade by antidepressants and related compounds of biogenic amine uptake into rat brain synaptosomes: most antidepressants selectively block norepinephrine uptake. Eur J Pharmacol 104: 227–286

    Google Scholar 

  62. Risby Ed, Hsiao Jk, Golden Rn, Potter Wz (1989) Intravenous alprazolam challenge in normal subjects. Biochemical, cardiovascular, and behavioral effects. Psychopharmacology 99 (4): 508–514

    PubMed  CAS  Google Scholar 

  63. Robertson Mm, Trimble Mr (1982) Major tranquilizers used as antidepressants. J Affect Dis 4: 173–193

    PubMed  CAS  Google Scholar 

  64. Sulser F (1984) Regulation and fuction of noradrenaline receptor systems in the brain. Neuro-pharmacology 23: 255–261

    CAS  Google Scholar 

  65. Ahlfors Kg, Baastrup Pc, Dencker Sj et al. (1981) Flupenthixoldecanoate in recurrent manic-depressive illness. Acta Psychiatr Scand 64: 226–237

    PubMed  CAS  Google Scholar 

  66. Alberts Jl, Francois F, Josserand F (1985) Etude des effects secondaires rapportés à l’occasion de traitements par dogmatil. Sem Hôp Paris 61: 1351–1357

    Google Scholar 

  67. Ansseau M, Ansoms C, Beckers G et al. (1984) Double-blind clinical study comparing alprazolam and doxepin in primary unipolar depression. J Affect Disord 7: 287–296

    PubMed  CAS  Google Scholar 

  68. Apa Task Force Report (1990) Benzodiazepine dependence, toxicity, and abuse. APA, Washington DC

    Google Scholar 

  69. Apelt S, Schmauss C, Emrich Hm (1992) Benzodiazepin-Entzugssyndrom und Abhängigkeitspotential von Alprazolam im Vergleich zu Diazepam. In: Gaebel W, Laux G (Hrsg) Biologische Psychiatrie. Synopsis 1990/91. Springer, Berlin Heidelberg New York Tokyo, S 407–408

    Google Scholar 

  70. Aylward M, Maddock J, Dewland Pm, Lewis Pa (1981) Sulpiride in depressive illness. Adv Biol Psychiatr 7: 154–165

    Google Scholar 

  71. Beckmann H, Haas S (1984) Therapie mit Benzodiazepinen: eine Bilanz. Nervenarzt 55: 111–122

    PubMed  CAS  Google Scholar 

  72. Benkert O, Holsboer F (1984) Effect of sulpiride in endogenous depression. Acta Psychiatr Scand 69 [Suppl 3111: 43–48

    Google Scholar 

  73. Bergdolt H, Karrass W (1983) Funktionelles kardiovaskuläres Syndrom. Herzneurotiker sind keine Simulanten. Therapie der Gegenwart 122: 20–30

    Google Scholar 

  74. Borenstein P, Cujo P, Champion C et al. (1968) Etude d’un nouveau psychotope; le sulpiride ( 1403 R.D). I. Method et resultats cliniques. Ann Méd Psychol 126: 90–99

    Google Scholar 

  75. Bouju B (1962) Contributions to the study of trimipramine in therapeutic psychiatry. Thesis, Paris

    Google Scholar 

  76. Bruynooghe F, geerts s, maele Gv, vögtle jun- Kert U (1992) Behandlung reaktiver Depressionen mit Sulpirid. Fortschr Med 110: 498–502

    PubMed  CAS  Google Scholar 

  77. Budde G (1992) Efficacy and tolerability of flupenthixol decanoate in the treatment of depression and psychosomatic disorders: a mul-ticenter trial in general practice. Prog Neuro- psychopharmacol Biol Psychiatry 16: 677–689

    CAS  Google Scholar 

  78. Budde G, Backhaus D, Beneke M, Rasmus W (1990) Depotneuroleptische Behandlung mit Fluanxol Depot versus Amitriptylin bei Patienten mit depressiver Symptomatik. Zentralbl Neurol Psychiatr 255: 269–270

    Google Scholar 

  79. Burckhardt D, Raeder E, Müller V et al. (1978) Cardiovascular effects of tricyclic and tetra-cyclic antidepressants. J Am Med Assoc 239: 213–216

    CAS  Google Scholar 

  80. Burke Bv, Sainsbury Mj, Mezo Ba (1967) A com- parative trial of amitriptyline and trimipramine in the treatment of depression. Med J Aust 1: 1216–1218

    PubMed  CAS  Google Scholar 

  81. Burns BN (1965) Preliminary evaluation of a new antidepressant, trimipramine, by a sequential method. Br J Psychiatry 11: 1155–1157

    Google Scholar 

  82. Cassidy S, Henry J (1987) Fatal toxicity of antidepressant drugs in overdose. Br Med J 295: 1021–1024

    CAS  Google Scholar 

  83. Chassard A, Carvet J, Setiey A, Robillard J (1985) Dogmatil for the treatment of combined asthenia, anxiety and depression in hospitalized elderly patients. A controlled trial, quantified according to the Hamilton Depression Scale. Sem Hôp 61: 2193–2198

    Google Scholar 

  84. Conway Jf (1981) Flupenthixol versus combined fluphenzin-nortriptyline in depressive illness. Practitioner 225: 400–404

    PubMed  CAS  Google Scholar 

  85. Coryell W, Moranville Jt (1989) Alprazolam for psychotic depression. Biol Psychiatry 25: 367–368

    Google Scholar 

  86. Cournoyer G, de montigny C, ouelleite J, lang- Lots R, elie r et al. (1987) A comparative double-blind controlled study of trimipramine and amitriptyline in major depression: lack of correlation with 5-hydroxytryptamine reuptake blockade. J Clin Psychopharmacol 7: 385–393

    PubMed  CAS  Google Scholar 

  87. Crome P, Newman B (1979) Fatal tricyclic antidepressant poisoning. J Roy Soc Med 72: 649–653

    Google Scholar 

  88. Damsbo N, Lassen T, Falhof Sl (1987) Flupentixol ( Fluanxol) or diazepam in the treatment of certain psychosomatic conditions. UgeskrLaeg 149: 12–16

    Google Scholar 

  89. Dawson Gw, Jue Sg, Brogden Rn (1984) Alprazolam: a review of its pharmacodynamic properties and efficacy in the treatment of anxiety and depression. Drugs 27: 132–147

    PubMed  CAS  Google Scholar 

  90. Deberdt R, Thio-Siebeling M, Parlevliet Dj (1980) Treatment of functional complaints with a weekly injection of a low dose of fluspirilene in anxious and asthenic patients. A double-blind placebo-controlled evaluation. Curr Ther Res 28: 857–866

    Google Scholar 

  91. Delor P, Leger Jm, Malauzat D (1985) Use of dogmatil (sulpiride) in elderly patients with depression. Sem Hôp 61: 3033–3037

    Google Scholar 

  92. Downing Rw, Rickels R (1974) Mixed anxiety-depression: fact or myth? Arch Gen Psychiatry 30: 312–317

    PubMed  CAS  Google Scholar 

  93. Draper Rj, Daly I (1983) Alprazolam compared with amitriptyline in depressive syndromes. Ir Med J 76: 453–456

    PubMed  CAS  Google Scholar 

  94. Edwards jg, inman whw, pearce gl, rawson Nsb (1991) Prescription-event monitoring of 10895 patients treated with alprazolam. Br J Psychiatry 158: 387–392

    PubMed  CAS  Google Scholar 

  95. Eigenmann Ak, Kuhn M (1989) Eosinophiles Lun- geninfiltrat mit Pneumothorax während Trimipramin-Behandlung. Dtsch Med Wochenschr 114: 1320–1323

    PubMed  CAS  Google Scholar 

  96. Eikmeier G, Muszynski K, Berger M, Gastpar M (1990) High-dose trimipramine in acute schizophrenia. Pharmacopsychiatry 23: 212–214

    PubMed  CAS  Google Scholar 

  97. Esparon J, Kolloori J, Naylor Gj et al. (1986) Comparison of the prophylactic action of flu- penthixol with placebo in lithium treated manic-depressive patients. Br J Psychiatry 148: 723–725

    PubMed  CAS  Google Scholar 

  98. Fabre Lf, Mclendon Dm (1980) Double-blind comparison of alprazolam and imipramine in depression. Curr Ther Res 27: 474–482

    Google Scholar 

  99. Fanget F, Bissuel Y, Marie Cardine M (1986) Value of low-dose dogmatil in the management of depressions. Sem Hôp 62: 69–72

    Google Scholar 

  100. Feighner JP (1986) A review of controlled studies of adinazolam mesylate in patients with major depressive disorder. Psychopharmacol Bull

    Google Scholar 

  101. -191

    Google Scholar 

  102. Feighner jp, aden gc, fabre lf, rickels k, smith Wt (1983) Comparison of alprazolam, imipramine and placebo in the treatment of depression. JAMA 249: 3057–3064

    Google Scholar 

  103. Frolund F (1974) Treatment of depression in general practice. A controlled trial of flupentixol. Curr Med Res Opin 2: 78–89

    PubMed  CAS  Google Scholar 

  104. Gastpar M (1989) Clinical originality and new biology of trimipramine. Drugs 38 [Suppl 11: 43–48

    Google Scholar 

  105. Gaultier M, Frejaville Jp (1973) A propos de 20 surdosages en sulpiride. J Eur Toxicol 6: 42–44

    CAS  Google Scholar 

  106. Grillage M (1986) Neurotic depression accompanied by somatic symptoms: a double-blind comparison of flupentixol and diazepam in general practice. Pharmatherapeutica 4 /9: 561–570

    PubMed  CAS  Google Scholar 

  107. Hamilton Ba, Jones Pg, Hoda An et al. (1989)Flupenthixol and fluvoxamine in mild to moderate depression: a comparison in general practice. Pharmatherapeutica 5: 292–297

    Google Scholar 

  108. Hassel P (1985) Experimental comparison of low doses of 1,5 mg fluspirilene and bromazepam in out-patients with psychovegetative disturbances. Pharmacopsychiatry 18: 297–302

    PubMed  CAS  Google Scholar 

  109. Heimann D (1985) Können bei abendlicher Einmaldosierung von Trimipramin Hypnotika/ Anxiolytika eingespart werden? Therapiewoche 35: 3–11

    Google Scholar 

  110. Holst B (1964) N 7009 in the treatment of anxiety states. Acta Psychiatr Scand 40: 415–419

    Google Scholar 

  111. Hostmaelingen Hj, Asskilt O, Austad Sg, Fjellheim H, Hostmaelingen Ea, Kristiansen Ph, Olsen Ti, Skotte T, Ofsti E (1989) Primary care treatment of depression in the elderly: a double-blind, multicentre study of flupenthixol („Fluanxol“) and sustained-release amitriptyline. Curr Med Res Opin 11: 593–599

    PubMed  CAS  Google Scholar 

  112. Hubain Pp, Castro P, Mesters P, De Maertelaer V, Mendlewicz J (1990) Alprazolam and amitriptyline in the treatment of major depressive disorder: a double-blind clinical and sleep EEG study. J Affect Disord 18: 67–73

    PubMed  CAS  Google Scholar 

  113. Johnson Daw (1979) A double-blind comparison of flupenthixol, nortriptyline and diazepam in neurotic depression. Acta Psychiatr Scand 59: 1–8

    PubMed  CAS  Google Scholar 

  114. Jokinen K, Koskinen T, Selonen R (1984) Flupenthixol versus diazepam in the treatment of psychosomatic disorders: a double-blind, multi-centre trial in general practice. Pharmatherapeutica 3: 573–581

    PubMed  CAS  Google Scholar 

  115. Juergens Sm, Morse Rm (1988) Alprazolam dependence in seven patients. Am J Psychiatry 145: 625–627

    PubMed  CAS  Google Scholar 

  116. Juillet P, Dorey R, Coreau P, Rancurel G (1962) Action of trimeproprimine (R.P. 7162) on some neurotic states. Ann Med Psychol (Paris) 1: 586–592

    Google Scholar 

  117. Kales A, Vgontzas An (1990) Not all benzodiazepines are alike. In: Stefanis Cn, Rabavilas Ad, Soldatos Cr (eds) Psychiatry — a world perspective. Elsevier, Amsterdam, pp 379–384

    Google Scholar 

  118. Kaiya H, Takeda N (1990) Sulpiride in the treatment of delusional depression. J Clin Psychopharmacol 10: 147–148

    PubMed  CAS  Google Scholar 

  119. Kielholz P, Terzani S, Pöldinger W (1979) The longterm treatment of periodical and cyclic depressions with flupenthixol decanoat. Int Pharmacopsychiatry 14: 305–309

    PubMed  CAS  Google Scholar 

  120. Kiltz Rr (1981) Depressionen nach Gabe von Imap® 1,5 mg. Munch Med Wochenschr 123: 611–612

    CAS  Google Scholar 

  121. kishimoto a, kamata k, sugihara t, ishiguro s, hazama h, mizukawa r, kunimoto n (1988) Treatment of depression with clonazepam. Acta Psychiatr Scand 77: 81–86

    Google Scholar 

  122. Kline Ns (1982) A controlled comparison of trimipramine and amitriptyline. J Clin Psychiatry 43: 100–104

    PubMed  CAS  Google Scholar 

  123. Kristof Fe, Lehmann He, Ban Ta (1967) Systematic studies with trimipramine — a new antidepres- sive drug. Can Psychiatr Assoc J 12: 517–520

    PubMed  CAS  Google Scholar 

  124. Laakmann G, Blaschke D, Hippius H, Messerer D (1986) Wirksamkeits-und Verträglichkeitsvergleich von Alprazolam gegen Amitriptylin bei der Behandlung von depressiven Patienten in der Praxis des niedergelassenen Allgemein-und Nervenarztes. In: Hippius H, Engel Rr, Laakmann G (Hrsg) Benzodiazepine: Rückblick und Ausblick. Springer, Berlin Heidelberg New York Tokyo, S 139–147

    Google Scholar 

  125. Lapierre YD (1989) A review of trimipramine. 30 years of clinical use. Drugs 38 [Suppl 11: 17–24

    Google Scholar 

  126. Laux G, König W (1985) Neues Anxiolytikum. Alprazolam — ein Triazolo-Benzodiazepin. Munch Med Wochenschr 127: 142–145

    Google Scholar 

  127. Laux G, Gunreben G (1991) Schwere Spätdystonie unter Fluspirilen. Dtsch Med Wochenschr 116: 977–980

    PubMed  CAS  Google Scholar 

  128. Lean Th, Sidhu Ms (1972) Comparative study of imipramine and trimipramine in depression associated with gynaecological conditions. Proc Obstet Gynaecol Soc 3: 222–228

    Google Scholar 

  129. Legal H-P (1975) Behandlung verschiedener psychosomatischer und altersbedingter Krankheitsbilder mit Dogmatil in der ambulanten Praxis. Z Allg Med 33: 1489–1491

    Google Scholar 

  130. Lehmann E (1987) Neuroleptanxiolyse: Neuroleptika in Tranquilizerindikation. In: Pichot P, Moller Hj (Hrsg) Neuroleptika — Rückschau 1952–1986, künftige Entwicklungen. Springer, Berlin Heidelberg New York Tokyo

    Google Scholar 

  131. Lehmann E (1989) The dose-effect relationship of 0,5, 1,0 and 1,5 mg Fluspirilen on anxious patients. Neuropsychobiology 21: 197–204

    CAS  Google Scholar 

  132. Lenox Rh, Shipley Je, Peyser Jm, Williams Jm, Weaver La (1984) Double-blind comparison of alprazolam versus imipramine in the inpatient treatment of major depressive illness. Psychopharmacol Bull 20: 79–82

    PubMed  CAS  Google Scholar 

  133. Lestynek Jl (1983) Sulpiride in depression. Sem Hôp 59: 2354–2357

    PubMed  CAS  Google Scholar 

  134. Luchins Dj, Oliver Ap, Wyatt Rj (1984) Seizures with antidepressants: an in vitro technique to assess relative risk. Epilepsia 25: 25–32

    PubMed  CAS  Google Scholar 

  135. Lydiard Rb, Laraia Mt, Ballenger Jc, Howell Ef (1987) Emergence of depressive symptoms in patients receiving alprazolam for panic disorder. Am J Psychiatry 144: 664–665

    PubMed  CAS  Google Scholar 

  136. Magni G, Conlon P, Arsie D (1987) Tricyclic antidepressants in treatment of cancer pain: a review. Pharmacopsychiatry 20: 160–164

    PubMed  CAS  Google Scholar 

  137. Majid J (1986) A double-blind comparison of once-daily flupenthixol and mianserin in depressed hospital out-patients. Pharmatherapeutica 4: 405–410

    PubMed  CAS  Google Scholar 

  138. Majid J, Swarbrick Dj (1983) A double-blind comparison of a single daily dose of 1 mg or 2 mg flupenthixol dihydrochlorid in the treatment of depression. J Int Biomet Inform Data 4: 13–17

    Google Scholar 

  139. Maragakis Bp (1990) A double-blind comparison of oral amitriptylin and low-dose intramuscular flupenthixol decanoate in depressive illness. Curr Med Res Opin 12: 51–57

    PubMed  CAS  Google Scholar 

  140. Marks I (1978) The benzodiazepines. Use, over- use, misuse, abuse. MTP Press, Lancaster

    Google Scholar 

  141. Mendels J, Schless Ap (1986) Comparative efficacy of alprazolam, imipramine and placebo administered once a day in treating depressed patients. J Clin Psychiatry 47: 357–361

    PubMed  CAS  Google Scholar 

  142. Meyers Cl, Vranckx C, Elgen K (1985) Psychosomatic disorders in general practice: comparison of treatment with flupenthixol, diazepam and sulpiride. Pharmatherapeutica 4 /4: 244–250

    PubMed  CAS  Google Scholar 

  143. Moffaert van M, dierick M, de meulemeester F, vereecken A (1983) Treatment of depressive anxiety states associated with psychosomatic symptoms. A double-blind multicentre clinical study: mianserin versus melitracen-flupentixol. Acta Psychiatr Belg 83: 525–539

    PubMed  Google Scholar 

  144. Moller H-J (1986) Neuroleptika als Tranquilizer: Indikationen und Gefahren. Med Min 81: 385–387

    CAS  Google Scholar 

  145. Moller H-J (1991) Niedrigdosierte Neuroleptika: Indikationen. In: POLDINGER W (Hrsg) Niedrig-dosierte Neuroleptika bei ängstlich-depressiven Zustandsbildern und psychosomatischen Erkrankungen. G Braun, Karlsruhe, S 52–61

    Google Scholar 

  146. Müller Rb (1975) Zur Therapie verschiedener Formen der Altersdepression mit Sulpirid (Dogmatil). Z Allg Med 33: 1546–154

    Google Scholar 

  147. Niskanen P, Tamminen T, Vinkari M (1975) SUl- piride vs. amitriptyline in the treatment of depression. Curr Ther Res 17: 281–284

    PubMed  CAS  Google Scholar 

  148. O’brien J (1977) A study of low dose amitriptyline overdoses. Am J Psychiatry 134: 66–68

    PubMed  Google Scholar 

  149. Osterheider M (1991) Flupentixol(decanoat) bei Patienten mit depressivem Syndrom. In: PÖLDINGER W (Hrsg) Niedrigdosierte Neuroleptika bei ängstlich-depressiven Zustandsbildern und psychosomatischen Erkrankungen. G Braun, Karlsruhe, S 97–107

    Google Scholar 

  150. Overall Je, Biggs J, Jacobs M, Holden K (1987) Comparison of alprazolam and imipramine for treatment of outpatient depression. J Clin Psychiatry 48: 15–19

    PubMed  CAS  Google Scholar 

  151. Ovhed J (1976) A double-blind study of flupenthixol (Fluanxol) in general practice. Curr Med Res Opin 4: 144

    PubMed  CAS  Google Scholar 

  152. Pach J (1989) Tardive Dyskinesien nach Tranquilizerbehandlung mit einem niedrig dosierten Depot-Neuroleptikum. Psyche 15: 681–685

    Google Scholar 

  153. Pach J, Waniek W (1976) Vergleichende Untersuchung zum Tranquilizer-Effekt von Fluspirilene und Diazepam. Pharmakopsychiatria 9: 61–66

    CAS  Google Scholar 

  154. Pach F, Waniek W, Papaspyrou D (1973) Zur Tranquilizer-Wirkung des Langzeit-Neuroleptikums Fluspirilene. Pharmakopsychiatria 6: 198–206

    Google Scholar 

  155. Paulmann F (1986) Behandlung von depressiven Störungen. Klinische Prüfung der relativen Wirksamkeit von Flupentixol im Vergleich zu Bromazepam. Fortschr Med 106: 218–222

    Google Scholar 

  156. Pecknold Jc, Mcclure Dj, Elie R, Appeltauer L, Wrzensinski L (1979) Trimipramine and amitriptyline: comparison in anxiety-depression. Curr Ther Res 26: 497–504

    Google Scholar 

  157. Poinso Y, Gouvernet J, Sambuc R (1988) A multicenter double-blind trial of sulpiride versus toloxatone in patients with reactive depressions and somatization receiving non-specialized care. Sem Hôp 64: 1201–1205

    Google Scholar 

  158. Pöldinger W (1991) (Hrsg) Niedrigdosierte Neuroleptika bei ängstlich-depressiven Zustandsbildern und psychosomatischen Erkrankungen. G Braun, Karlsruhe

    Google Scholar 

  159. Predescu V, Ciurezu T, Timofte G, Roman J (1973) Symptomatic relief with flupentixol ( Fluanxol) of the anxious-algetic-depressive syndrome complex in neurotic states. Acta Psychiatr Scand 49: 15–27

    Google Scholar 

  160. Rama Rao Va, Bailey J, Bishop M, Coppen A (1981) A clinical pharmacodynamic evaluation of sulpiride. Psychopharmacology 73: 77–80

    Google Scholar 

  161. Reiter Pj (1969) On flupentixol, an antidepressant of a new chemical group. Br J Psychiatry 115: 1399–1402

    PubMed  CAS  Google Scholar 

  162. Rickels K (1985) Alpralozam in the management of anxiety. In: Lader Mh, Davies Hc (eds) Drug treatment of neurotic disorders–focus on alprazolam. Churchill Livingstone, Edinburgh, pp 84–93

    Google Scholar 

  163. Rickels K, Gordon Pe, Weise Cc, Bazilian Se et al. (1970) Amitriptyline and trimipramine in neurotic depressed outpatients–a collaborative study. Am J Psychiatry 127: 208–218

    PubMed  CAS  Google Scholar 

  164. Rickels R, Smith W, Feighner Jp (1982) Alprazolam, imipramine and placebo in the treatment of major depressive disorder. Curr Ther Res 32: 157–164

    Google Scholar 

  165. Rickels K, Feighner Jp, Smith Wt (1985) Alprazolam, amitriptyline, doxepin and placebo in the treatment of depression. Arch Gen Psychiatry 42: 134–141

    PubMed  CAS  Google Scholar 

  166. Rickels K, Chung Hr, Csanalosi Ib, Hurowitz Am, London J, Wiseman K, Kaplan M, Amster-Dam Jd (1987) Alprazolam, diazepam, imipramine and placebo in outpatients with major depression. Arch Gen Psychiatry 44: 862–866

    PubMed  CAS  Google Scholar 

  167. Rifkin A, Saraf K, Kane J, Ross D, Klein Df (1980) A comparison of trimipramine and imipramine: a controlled study. J Clin Psychiatry 41: 124–129

    PubMed  CAS  Google Scholar 

  168. Roberston Mm, Trimble Mr (1981) Neuroleptics as antidepressants. Neuropharmacology 20: 173–193

    Google Scholar 

  169. Robertson Mm, Trimble Mr (1982) Major tranquilizers used as antidepressants. J Affect Dis 4: 173–193

    Google Scholar 

  170. Rosenberg Ju, Ostensen J, Fonnelop H (1976) Flupentixol-nortriptylinic in the treatment of patients with anxiety-depression-asthenia (the „ADA syndrome“). Tidsskr Nor Laegeforen 96: 229–233

    PubMed  CAS  Google Scholar 

  171. Rush Aj, Erman Mk, Schlesser Ma, Roffwarg Hp, Vasavada N, Khatami M, Fairchild C, Giles De (1985) Alprazolam vs amitriptyline in depression with reduced REM latencies. Arch Gen Psychiatry 42: 1154–1159

    PubMed  CAS  Google Scholar 

  172. Wither E (1989) Depression, circadian rhythms and trimipramine. Drugs 38 [Suppl 1]: 1–3

    Google Scholar 

  173. Saletu B, Schanda H, Grunberger J (1976) The treatment of endomorphus and psychogenic depressions with a fixed combination of amitriptyline/flupentixol (Lu 7410). Int Pharmacopsychiatry 11: 109–128

    PubMed  CAS  Google Scholar 

  174. Salminen Jk, Lehtonen V (1980) Sulpiride in depression: plasma levels and effects. Curr Ther Res 27: 109–115

    Google Scholar 

  175. Salzmann Mm (1965) A controlled trial with trimipramine, a new antidepressant drug. Br J Psychiatry 111: 1105–1106

    PubMed  CAS  Google Scholar 

  176. Schatzberg Af, Cole Jo (1978) Benzodiazepines in depressive disorders. Arch Gen Psychiatry 35: 1359–1365

    PubMed  CAS  Google Scholar 

  177. Schmidt Lg (1989) Utilisation and safety of fluspirilene in nonpsychotic outpatients. Pharmacopsychiatry 22: 188–191

    PubMed  CAS  Google Scholar 

  178. Settle Ec, Ayd Fj (1980) Trimipramine: twenty years’ worldwide experience. J Clin Psychiatry 41: 266–274

    PubMed  Google Scholar 

  179. Sieberns S (1982) Erfahrungen mit Flupentixoldecanoat (Fluanxol Depot) bei der Behandlung depressiver Verstimmungszustände. Therapiewoche 32: 1184–1189

    Google Scholar 

  180. Sieberns S, Budde G (1990) Niedrigdosierte Neu- roleptika bei ängstlich-depressiven Syndromen — Nutzen und Risiko. In: Lungershausen E, Kaschka Wp, Witkowski Rj (HIsg) Affektive Psychosen. Schattauer, Stuttgart, S 346–353

    Google Scholar 

  181. Simpson gm, pi eh, gross l, baron d, November M (1988) Plasma levels and therapeutic response with trimipramine treatment of endogenous depression. J Clin Psychiatry 49: 113–116

    PubMed  CAS  Google Scholar 

  182. Singh An, Nair Npv, Suranyi-Cadoiie B, Schwartz G, Lizondo E (1988) A double blind comparison of alprazolam and amitriptyline hydrochloride in the treatment of nonpsychic depression. Can J Psychiatry 33: 218–222

    PubMed  CAS  Google Scholar 

  183. Standish-Barry Hmas, Bouras N, Bridges Pk, Watson Jp (1983) A randomized double blind group comparative study of sulpiride and amitriptyline in affective disorder. Psycho-pharmacology 81: 258–260

    CAS  Google Scholar 

  184. Strahan A, Rosenthal J, Kaswan M, Winston A (1985) Three case reports of acute paroxysmal excitement associated with alprazolam treatment. Am J Psychiatry 142: 859–861

    PubMed  CAS  Google Scholar 

  185. Tam W, Young Jpr, John G, Lader Mh (1982) A controlled comparison of flupenthixol decanoate injections and oral amitriptyline in depressed out-patients. Br J Psychiatry 140: 287–291

    Google Scholar 

  186. Tegeler J, Lehmann E, Weiher A, Heinrich K (1989) Tolerability of long-term treatment with fluspirilene 1,5 mg per week. Pharmacopsychiatry 22: 218–221

    Google Scholar 

  187. Thilmann J (1983) Leitsymptom Angst und Spannung und deren somatische Begleiterscheinungen. Multizentrische Prüfung Fluspirilene versus Bromazepam. Fortschr Med 101: 1676–1678

    PubMed  CAS  Google Scholar 

  188. vallé jones jc, swarbrick dj (1981) Once daily flupenthixol in the treatment of elderly depressed patients: a multicentre trial in general practice. Curr Med Res Opin 7: 543–549

    Google Scholar 

  189. Weissman Mm, Prusoff Ba, Kleber Hd, Sholomskas Aj, Rounsaville Bj (1985) Alprazolam (Xanax®) in the treatment of major depressi- on. In: Burrows Gd, Norman Tr, Dennerstein L (eds) Clinical and pharmacological studies in psychiatric disorders. Libbey, London, pp 52–58

    Google Scholar 

  190. Wheatley Dp (1983) Antidepressant effect of flupenthixol compared to mianserin. J Int Biomet Inform Data 4: 5–12

    Google Scholar 

  191. Wiegand M, Berger M, Zulley J, Von Zerssen D (1986) The effect of trimipramine on sleep in patients with major depressive disorder. Pharmacopsychiatry 19: 198–199

    CAS  Google Scholar 

  192. Wiesel Fa, Alfredson G, Bjerkenstedt L, Harnryd C, Oxenstierna G, Sedval G (1985) Le dogmatil dans le traitement des symptômes negatifs chez des patients schizophrènes. Sem Hôp Paris 61: 1317–1321

    Google Scholar 

  193. Young Jpr, Hughes Wc, Lader Mh (1976) A controlled comparison of flupenthixol and amitriptyline in depressed outpatients. Br Med J I: 1116–1118

    Google Scholar 

  194. Yura R, Shibahara Y, Fukushima Y, Sato M (1976) A doubleblind comparative study of the effects of sulpiride and imipramine on depression. Clin Psychiatry 18: 89–102

    Google Scholar 

  195. Abernethy Dr,Greenblatt Dj, DIVOLL M et al. (1983) Interaction of cimetidine with the triazolobenzodiazepines alprazolam and triazolam. Psychopharmacology 80: 275–278

    Google Scholar 

  196. Arana gw, epstein s, molloy m et al. (1988) Carbamazepine-induced reduction of plasma alprazolam concentrations: a clinical case report. J Clin Psychiatry 49: 448–449

    PubMed  CAS  Google Scholar 

  197. Ciraulo da, barnhill jg, greenblatt dj, shader Ri et al. (1988) Abuse liability and clinical pharmacokinetics of alprazolam in alcoholic men. J Clin Psychiatry 49: 333–337

    PubMed  CAS  Google Scholar 

  198. Diehl Lw (1985) Die Bedeutung der Blutspiegeluntersuchungen für die Therapie epileptischer Verstimmungen und Psychosen. Nervenarzt 56: 383–387

    PubMed  CAS  Google Scholar 

  199. Douyon R, Angrist B, Peselow E, Cooper T, Rotrosen J (1989) Neuroleptic augmentation with alprazolam: clinical effects and pharmacokinetic correlates. Am J Psychiatry 146: 231–234

    PubMed  CAS  Google Scholar 

  200. Evans rl, nelson mv, melethil s et al. (1990) Evaluation of the interaction of lithium and alprazolam. J Clin Psychopharmacol 10: 355–359

    PubMed  CAS  Google Scholar 

  201. Lasher Ta, Fleishaker Jc, Steenwyk Rc, Antal Ej (1991) Pharmacokinetic pharmacodynamic evaluation of the combined administration of alprazolam and fluoxetine. Psychopharmacology 104: 323–327

    PubMed  CAS  Google Scholar 

  202. Linnoila M, Mattila Mj (1973) Drug interaction on psychomotor skills related to driving, diazepam and alcohol. Eur J Clin Pharmacol 5: 186–194

    CAS  Google Scholar 

  203. Schuckit Ma (1987) Alcohol and drug interactions with antianxiety medications. Am J Med 82 [Suppl 5A]: 27–33

    PubMed  CAS  Google Scholar 

  204. Seppala T (1976) Effect of chlorpromazine or sulpiride and alcohol on psychomotor skills related to driving. Arch Int Pharmacodyn 223: 311

    PubMed  CAS  Google Scholar 

  205. Wells bg, evans rl, ereshefsky l, antal ej et al. (1988) Clinical outcome and adverse effect profile associated with concurrent administration of alprazolam and imipramin. J Clin Psychiatry 49: 394 - -399

    PubMed  CAS  Google Scholar 

  206. Wolkowitz Om, pickar D, doran ar et al. (1986) Combination alprazolam-neuroleptic treat- ment of the positive and negative symptoms of schizophrenia. Am J Psychiatry 143: 85–87

    PubMed  CAS  Google Scholar 

  207. Baldessarini Rj (1990) Drugs and treatment of psychiatric disorders, miscellaneus medical uses for neuroleptic drugs. In: Goodman Ls, Gilman A, Gilman Ag (eds) The pharmacological basis of therapeutics. Pergamon, New York Oxford, pp 383–435

    Google Scholar 

  208. Glassman Ah, Bigger Jt (1981) Cardiovascular effects of therapeutic doses of tricyclic antidepressants. Arch Gen Psychiatry 38: 815–820

    PubMed  CAS  Google Scholar 

  209. Grohmann R, hippius H, müller-oerlinghausen B et al. (1984) Assessment of adverse drug re- actions in psychiatric hospitals. Eur J Clin Pharmacol 26: 727–734

    PubMed  CAS  Google Scholar 

  210. Möller Hj, Meier K, Wernicke T (1988) Empirical investigation on the risk of agranulocytosis/ leucopenia under medication with antidepressants. Pharmacopsychiatry 21: 304–305

    PubMed  Google Scholar 

  211. Spiess-Kiefer C, Grohmann R (1987) Psychopharmaka-induzierte Blutbildveränderungen. Minch Med Wochenschr 129: 173–175

    Google Scholar 

  212. Tornatore Fl, Stramek Jj, Okeya Bl, Pi Eh (1991) Unerwünschte Wirkungen von Psychopharmaka. G Thieme, Stuttgart

    Google Scholar 

  213. Basu S, Singh S, Sanyal Ak (1977) Malformations of internal organs induced by trimipramine maleate in chick embryos. J Anat Soc India 26: 125–129

    CAS  Google Scholar 

  214. Basu S, Singh S, Sanyal Ak (1978) Skeletal malformations induced by trimipramine maleate in chick embryos. Ann Natl Acad Med Sci Ind 14: 92–99

    Google Scholar 

  215. Budde G, Sieberns S (1991) Niedrigdosierte Neuroleptika bei ängstlich-depressiven Syndromen: Nutzen und Risiko. In: Poldinger W (Hrsg) Niedrigdosierte Neuroleptika. G Braun, Karlsruhe

    Google Scholar 

  216. Hussain Mz, Chaudhry Za (1973) Single versus divided daily dose of trimipramine in the treatment of depressive illness. Am J Psychiatry 130: 1142–1144

    PubMed  CAS  Google Scholar 

  217. Johnson Daw (1979) A double-blind comparison of flupenthixol, nortriptyline and diazepam in neurotic depression. Acta Psychiatr Scand 59: 1–8

    PubMed  CAS  Google Scholar 

  218. laux g, könig w (1985) Neues Anxiolytikum. Alprazolam — ein Triazolo-Benzodiazepin. Munch Med Wochenschr 127: 142–145

    Google Scholar 

  219. Laux G, Pfaff G, Daniel D, König W, Marx D (1984) Antidepressive Wirksamkeit, Verträglichkeit und Dexamethason-HemmtestErgebnisse der intravenösen Infusionstherapie mit Trimipramin bei schweren depressiven Erkrankungen. 14. CINP Kongreß, Florenz

    Google Scholar 

  220. Lehmann E, Heinrich K, Wurthmann C (1990) Niedrigdosierte Neuroleptanxiolyse. In: HEINRICH K (Hrsg) Leitlinien neuroleptischer Therapie. Springer, Berlin Heidelberg New York Tokyo, S 155–165

    Google Scholar 

  221. Müller-Oerlinghausen B (1989) Nutzen — Risiko — Beurteilung von Benzodiazepinen. Dtsch Ärztebi 86: 636–637

    Google Scholar 

  222. Poldinger W (1991) (Hrsg) Niedrigdosierte Neuroleptika bei ängstlich-depressiven Zustandsbildern und psychosomatischen Erkrankungen. G Braun, Karlsruhe

    Google Scholar 

  223. Rùther E, Hippius H (1982) Neuroleptika in niedriger Dosierung als Tranquilizer? Munch Med Wochenschr 124: 683–684

    Google Scholar 

  224. Settle Ec, Ayd Fj (1980) Trimipramine: twenty years’ worldwide experience. J Clin Psychiatry 41: 266–274

    PubMed  Google Scholar 

  225. Sieberns S, Budde G (1990) Niedrigdosierte Neu- roleptika bei ängstlich-depressiven Syndromen — Nutzen und Risiko. In: Lungershausen E, Kaschka Wp, Witkowski Rj (Hrsg) Affektive Psychosen. Schattauer, Stuttgart, S 346–353

    Google Scholar 

  226. Smith R, Amin Mm, Ban Ta (1978) Trimipramine in the treatment of depression: a comparison of single vs divided dose administration. Psychopharmacol Bull 14: 42–43

    PubMed  CAS  Google Scholar 

  227. Tam W, Young Jpr, John G, Lader Mh (1982) A controlled comparison of flupenthixol decanoate injections and oral amitriptyline in depressed out-patients. Br J Psychiatry 140: 287–291

    PubMed  CAS  Google Scholar 

  228. Webster Pac (1973) Withdrawal symptoms in neonates associated with maternal antidepressant therapy. Lancet ii: 319

    Google Scholar 

  229. Young Jpr, Hughes Wc, Lader Mh (1976) A controlled comparison of flupenthixol and amitriptyline in depressed out-patients. Br Med J I: 1116–1118

    Google Scholar 

  230. David I, Albrecht V, Filip V, Höschl C, Palljs M, Dvorak I, Praskova H (1989) The effects of single-dose administration of Levoprotiline and Maprotiline on the TOPO-EEG in depression. ECNP-Congress, Göteborg (Abstract )

    Google Scholar 

  231. Delini-Stula A, Mogilnicka E (1988) Single treatments with the antidepressants Oxaprotiline and its and enatiomers increases behavioral, responses to dopaminergic stimulation in the rat. J Neural Transm 71: 91–98

    PubMed  CAS  Google Scholar 

  232. Delini-Stuta A, Mogilnicka E (1989) Rapid changes in functional responsiveness of the 5-HT system after single-dose and multiple-dose treatment with antidepressants: effects of Maprotiline and Oxaprotiline and its enantiomers. J Psychopharmacol 3: 7–13

    Google Scholar 

  233. Delini-Stula A, Radeke E, Van Riezen H (1988) Enhanced functional responsiveness of the dopaminergic system–the mechanism of anti-immobility effects of antidepressants in the behavioral dispair test in rat. Neuropharmacology 27: 143–197

    Google Scholar 

  234. Faltus F, Wendt G (1990) Beeinflussung von Eßstörungen durch Levoprotilin. Minch Med Wochenschr 132: 62–64

    Google Scholar 

  235. Hippius H (1990) Neueste Entwicklungen auf dem Gebiet der medikamentösen antidepressiven Therapie: Medikamentöse Therapie affektiver Psychosen. Munch Med Wochenschr 132: 3–4

    Google Scholar 

  236. Maj J, Rogöz Z, Skuza G, Sowinska H (1990) Some central pharmacological effects of and Oxaprotiline. J Neural Transm 80: 129–143

    CAS  Google Scholar 

  237. Matussek N (1990) Neueste Entwicklungen auf dem Gebiet der medikamentösen antidepressiven Therapie: MAO-Hemmer, Levoprotilin, Antikonvulsiva. Munch Med Wochenschr 132: 91–92

    Google Scholar 

  238. Mogilnicka E, Zazula M, Wedzony K (1987) Functional supersensitivity to the alpha-l-adrenoreceptors agonist after repeated treatment with antidepressant drugs is not conditioned by beta-down-regulation. Neuropharmacology 26: 1457–1461

    PubMed  CAS  Google Scholar 

  239. Nahunek K, Svestka J, Ceskova E, Rysanek R, Obrovska V, Misurec J, Wendt G (1990) Position von Levoprotilin in der Klassifikation antidepressiv wirksamer Präparate nach Nahunek. Munch Med Wochenschr 132: 50–54

    Google Scholar 

  240. Pelzer E, Unverzagt C, Koppetz R, Dörnemann H, Moller Hj (1990) Depression und Schlaf — differentielle Effekte dreier Antidepressiva. Munch Med Wochenschr 132: 55–57

    Google Scholar 

  241. Schoenmakers Eajm, Robbe Hw, O’hanion Jf (1988) Levoprotiline, a novel antidepressant and automobile driving performance. 16. CINP-Congress, München (Abstracts)

    Google Scholar 

  242. Vinar O, Klein Df, Potter Wz, Gause Em (1991) A survey of psychotropic medications not available in the United States. Neuropsychopharmacology 5: 201–217

    PubMed  CAS  Google Scholar 

  243. Wendt G (1990) Levoprotiline: clinical therapeutic efficacy and tolerability. In: Bunney We et al. (eds) Neuropsychopharmacology. Springer, Berlin Heidelberg New York Tokyo, pp 294–305

    Google Scholar 

  244. Wendt G, Binz U (1990) Levoprotiline — Therapeutische Wirksamkeit und Verträglichkeit am Beispiel einer Doppelblindstudie vs. Amitriptylin. Munch Med Wochenschr 132: 44–49

    Google Scholar 

  245. Wolfersdorf M, Wendt G, Binz U, Steiner B, Hole G (1988) CGP 12.103 versus clomipramine in the treatment of depressed inpatients — results of a double-blind study. Pharmacopsychiatry 21: 203–207

    PubMed  CAS  Google Scholar 

Download references

Authors
  1. G. Laux
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A. Delini-Stula
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. U. Breyer-Pfaff
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. K. Rickels
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. M. Osterheider
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. S. Sieberns
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. K. Heininger
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. T. Becker
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. O. Dietmaier
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. G. Wendt
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Klinische Neurochemie, Psychiatrische Universitätsklinik, Füchsleinstraße 15, D-97080, Würzburg, Bundesrepublik Deutschland

    Peter Riederer

  2. Psychiatrische Universitätsklinik, Sigmund-Freud-Straße 25, D-53105, Bonn, Bundesrepublik Deutschland

    Gerd Laux

  3. Psychiatrische Universitätsklinik, Wilhelm Klein-Straße 27, CH-4025, Basel, Schweiz

    Walter Pöldinger

Rights and permissions

Reprints and permissions

Copyright information

© 1993 Springer-Verlag/Wien

About this chapter

Cite this chapter

Laux, G. et al. (1993). Atypische Antidepressiva. In: Riederer, P., Laux, G., Pöldinger, W. (eds) Neuro-Psychopharmaka. Springer, Vienna. https://doi.org/10.1007/978-3-7091-3317-0_5

Download citation

  • DOI: https://doi.org/10.1007/978-3-7091-3317-0_5

  • Publisher Name: Springer, Vienna

  • Print ISBN: 978-3-7091-3318-7

  • Online ISBN: 978-3-7091-3317-0

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation